VBP1: A Potential Drug Target for VHL Syndrome (G7411)

Target Name: VBP1

NCBI ID: G7411

VBP1

VBP1: A Potential Drug Target for VHL Syndrome

Von Hippel-Lindau (VHL) syndrome is a rare genetic disorder that is characterized by the development of tumors, including melanoma, and the formation of blood vessels that feed into those tumors. It is a serious and life-threatening condition that affects approximately 50 people worldwide. The discovery of the von Hippel-Lindau syndrome (VHL) gene in 1990 has led to a greater understanding of the underlying genetic and molecular mechanisms that lead to the development of this condition. One of the proteins that has been identified in the VHL gene is the von Hippel-Lindau-binding protein 1 (VBP1). This protein is of interest as a potential drug target or biomarker for the treatment of VHL syndrome and other related conditions.

The VHL gene is located on chromosome 1p36 and encodes a protein that is critical for the development and maintenance of normal blood vessels. The protein is composed of 156 amino acids and has a calculated molecular weight of 17.9 kDa. VBP1 is a protein that is expressed in a variety of tissues, including the brain, heart, and blood vessels. It is also known as VHL-1 and has been shown to be involved in the development and maintenance of blood vessels, as well as the regulation of cell growth and differentiation.

One of the key functions of VBP1 is its ability to interact with the von Hippel-Lindau protein (VHL). VHL is a protein that is characterized by the presence of a hypervariable region (HVR) that is responsible for the diversity of VHL proteins. VBP1 has been shown to interact with VHLH, a variant of VHL that is characterized by the presence of an additional 24 amino acid residues at its C-terminus. This interaction between VBP1 and VHLH is important for the regulation of the development and maintenance of blood vessels.

In addition to its interaction with VHL, VBP1 is also involved in the regulation of cell growth and differentiation. It has been shown to play a role in the regulation of angiogenesis, the formation of new blood vessels, and the regulation of vascular permeability . VBP1 has also been shown to be involved in the regulation of cell adhesion and cell-cell interactions, as well as the regulation of cell cycle progression.

The discovery of VBP1 as a potential drug target or biomarker for VHL syndrome has important implications for the treatment of this condition. Currently, there are no approved therapies for VHL syndrome. The only treatment options available are surgical interventions, such as surgery to remove the tumor or radiation therapy, and supportive care, such as chemotherapy and blood transfusions. These treatments are often effective in managing the symptoms of VHL syndrome, but they are not effective in preventing the development of new tumors or in curing the condition.

VBP1 is a potential drug target or biomarker for VHL syndrome because it is involved in the regulation of blood vessels and cell growth and differentiation. By targeting VBP1 with drugs, it may be possible to prevent the development of new tumors and improve the treatment outcomes for people with VHL syndrome. Additionally, VBP1 may also be used as a biomarker to monitor the effectiveness of therapies for VHL syndrome.

Conclusion

Von Hippel-Lindau-binding protein 1 (VBP1) is a protein that is characterized by its involvement in the regulation of blood vessels and cell growth and differentiation. The discovery of VBP1 as a potential drug target or biomarker for VHL syndrome has important implications for the treatment of this condition. Further research is needed to understand the full role of VBP1 in the development and maintenance of blood vessels and to explore its potential as a drug target or biomarker for VHL syndrome.

Protein Name: VHL Binding Protein 1

Functions: Binds specifically to cytosolic chaperonin (c-CPN) and transfers target proteins to it. Binds to nascent polypeptide chain and promotes folding in an environment in which there are many competing pathways for nonnative proteins

The "VBP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VBP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets